Daxor Corporation DXR

Company Overview

Daxor Corporation (NYSE American: DXR) is a U.S.-based medical technology and healthcare company focused on blood volume measurement and diagnostic analytics. The company operates primarily in the healthcare technology and medical diagnostics industries, with its core business centered on the development, commercialization, and support of the BVA-100 Blood Volume Analyzer, a diagnostic system designed to measure a patient’s blood volume and optimize fluid management in clinical settings. The company’s technology is used by hospitals, physicians, and healthcare systems treating conditions such as heart failure, critical illness, surgery recovery, and complex fluid-balance disorders.

Daxor traces its origins to a broader biotechnology and diagnostics business before evolving into a specialized medical technology company focused on blood-volume diagnostics and personalized fluid management. Over time, the company concentrated its strategy around proprietary blood-volume analysis technology and related clinical applications. Its positioning is based on offering quantitative blood-volume assessment intended to improve treatment precision compared with traditional estimation methods commonly used in hospital care.

Business Operations

Daxor generates revenue primarily through the sale, leasing, servicing, and clinical utilization of the BVA-100 Blood Volume Analyzer system and associated diagnostic services. The company’s operations are concentrated in the United States, where it works with hospitals, academic medical centers, and healthcare providers. Daxor also supports clinical research and data-driven applications tied to blood-volume measurement, including efforts to integrate diagnostics into broader cardiovascular and critical-care workflows.

The company’s operations include proprietary diagnostic technologies, software-supported analytics, and intellectual property related to blood-volume measurement methodologies. Daxor has also been involved in clinical education initiatives and partnerships with healthcare institutions aimed at expanding physician adoption and validating the clinical utility of blood-volume analysis. Public disclosures indicate that the company’s business structure is relatively focused compared with larger diversified medical device manufacturers, with a significant concentration around its core diagnostic platform.

Strategic Position & Investments

Daxor’s strategic direction has emphasized expanding clinical adoption of quantitative blood-volume analysis in cardiovascular medicine, intensive care, and hospital fluid-management programs. Growth initiatives have included increasing utilization within hospital systems, strengthening reimbursement visibility, and supporting additional clinical validation studies intended to broaden acceptance among physicians and healthcare administrators. The company has also promoted the use of data analytics and patient-monitoring approaches tied to personalized medicine and precision diagnostics.

The company has pursued investments in technology enhancement, clinical research, and healthcare data applications associated with circulatory health and fluid optimization. Daxor has highlighted opportunities linked to heart failure management, an area of increasing healthcare expenditure and hospital utilization in the United States. Publicly available information does not indicate a large acquisition-driven strategy comparable to major medical technology conglomerates, and data regarding extensive international subsidiaries or large-scale portfolio holdings is inconclusive based on available public sources.

Geographic Footprint

Daxor is headquartered in the United States, with operations primarily focused on the domestic healthcare market. Its commercial presence has historically centered on U.S. hospitals and healthcare systems, particularly institutions involved in cardiovascular medicine, critical care, and advanced diagnostics. The company’s technology has been referenced in clinical and academic settings across multiple regions within the country.

While Daxor’s products and research have received attention internationally through medical publications and clinical collaboration, publicly available information indicates that its operational footprint remains significantly concentrated in North America. Data regarding large-scale operational infrastructure in Europe, Asia-Pacific, Latin America, or the Middle East is limited based on available public disclosures.

Leadership & Governance

Daxor’s leadership has historically reflected a physician-led and clinically focused governance approach, emphasizing evidence-based medicine, diagnostic precision, and hospital adoption of quantitative measurement technologies. The company’s strategic vision has centered on improving patient outcomes through more accurate assessment of blood volume and individualized fluid-management decisions.

Key executives and leadership figures include:

• Michael Feldschuh, MD – Chairman and Chief Executive Officer
• Franz R. Matzner – Director
• Barry A. Freeman – Director
• Ari Feldschuh – Executive Vice President

Public filings indicate that leadership and governance activities are overseen through a board structure typical of publicly traded healthcare technology companies, with emphasis on regulatory compliance, clinical validation, and commercialization strategy. Some executive and governance details may change over time based on annual filings and corporate disclosures.